Yvette Bernal
Overview
Explore the profile of Yvette Bernal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
3874
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wudhikarn K, King A, Geyer M, Roshal M, Bernal Y, Gyurkocza B, et al.
Blood Adv
. 2022 Jan;
6(5):1432-1443.
PMID: 35042232
Novel monoclonal antibody (mAb)-based therapies targeting CD19 and CD22 (blinatumomab and inotuzumab) have shown high rates of complete remission (CR) and been used as a bridging treatment to potentially curative...
2.
Perica K, Flynn J, Curran K, Rivere I, Wang X, Senechal B, et al.
Leukemia
. 2021 Mar;
35(11):3268-3271.
PMID: 33686196
No abstract available.
3.
Sauter C, Senechal B, Riviere I, Ni A, Bernal Y, Wang X, et al.
Blood
. 2019 Jul;
134(7):626-635.
PMID: 31262783
High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) is the standard of care for relapsed or primary refractory (rel/ref) chemorefractory diffuse large B-cell lymphoma. Only 50% of patients are cured...
4.
Geyer M, Riviere I, Senechal B, Wang X, Wang Y, Purdon T, et al.
JCI Insight
. 2019 Apr;
5.
PMID: 30938714
Background: Subgroups of patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) exhibit suboptimal outcomes after standard therapies, including oral kinase inhibitors. We and others have previously reported on...
5.
Santomasso B, Park J, Salloum D, Riviere I, Flynn J, Mead E, et al.
Cancer Discov
. 2018 Jun;
8(8):958-971.
PMID: 29880584
CD19-specific chimeric antigen receptor (CAR) T-cell therapy is highly effective against relapsed or refractory acute lymphoblastic leukemia (ALL), but is hindered by neurotoxicity. In 53 adult patients with ALL, we...
6.
Maslak P, Dao T, Bernal Y, Chanel S, Zhang R, Frattini M, et al.
Blood Adv
. 2018 Feb;
2(3):224-234.
PMID: 29386195
A National Cancer Institute consensus study on prioritization of cancer antigens ranked the Wilms tumor 1 (WT1) protein as the top immunotherapy target in cancer. We previously reported a pilot...
7.
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K, et al.
Sci Transl Med
. 2014 Feb;
6(224):224ra25.
PMID: 24553386
We report on 16 patients with relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL) that we treated with autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) specific...
8.
Brentjens R, Davila M, Riviere I, Park J, Wang X, Cowell L, et al.
Sci Transl Med
. 2013 Mar;
5(177):177ra38.
PMID: 23515080
Adults with relapsed B cell acute lymphoblastic leukemia (B-ALL) have a dismal prognosis. Only those patients able to achieve a second remission with no minimal residual disease (MRD) have a...
9.
Brentjens R, Riviere I, Park J, Davila M, Wang X, Stefanski J, et al.
Blood
. 2011 Aug;
118(18):4817-28.
PMID: 21849486
We report the findings from the first 10 patients with chemotherapy-refractory chronic lymphocytic leukemia (CLL) or relapsed B-cell acute lymphoblastic leukemia (ALL) we have enrolled for treatment with autologous T...
10.
Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M
Mol Ther
. 2010 Apr;
18(4):666-8.
PMID: 20357779
No abstract available.